In the treatment of lung cancer, chemotherapy has become a generally accepted and widely applied therapeutic modality. Since the majority of patients with this disease are not cured by surgery or radiotherapy, and also because many cases present with advanced stages of disease, chemotherapy is regarded as the most promising approach to the ultimate control of lung cancer.
In small cell tumors, significant advances in therapy have produced striking results [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . The non-small cell tumors, however, have remained relatively refractory to treatment [1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
The premise upon which chemotherapy is based is that of eradication of tumor by cytodestruction. Optimally, effective therapy should demonstrate selective toxicity to tumor cells with little or tolerable damage to normal tissues. In practice, this has been difficult to achieve. Drug treatment has evolved, however, from empiric considerations of cell kinetics, the pharmacologic basis of antineoplastic agents, and metabolic aspects of tumor growth [16] [17] [18] .
Hodgkin's disease, and breast cancer [19] [20] [21] [22] . The rationale for combination chemotherapy is based upon the concept that the effectiveness of antitumor agents may be enhanced by concurrent and sequential inhibition of metabolic pathways for DNA biosynthesis [23] , which could yield additive or synergistic effects. Additionally, it is possible that the use of multiple agents, by analogy to antibiotic usage in the management of infectious disease, could reduce the development of drug resistance [24] . In actual clinical practice, however, combinations of drugs are generally selected on the basis of known effectiveness of each component drug in the disease and divergent toxicity of the component drugs.
Despite the widespread use of combination chemotherapy, relatively little attention has been given to possible detrimental results. Drug interactions could prove to be antagonistic, so that agents, known to be effective when used singly, would become ineffective in combination. There is also the potential for ineffectiveness of a known active compound, when used in combination, due to the dose-response requirements of the individual agent. Combinations generally include doses lower than those used when compounds are administered singly. Certain agents, to be effective, may require higher doses to elicit a response than those doses employed in combinations. In the design of clinical trials with drugs in combinations, consideration of these possible adverse effects is merited.
NON-SMALL CELL CARCINOMA In evaluating antitumor response in patients with non-small cell carcinoma, the effectiveness of treatment may be assessed in relation to cell type and stage of disease (Table 1) [25, 26] .
Early studies with single agent chemotherapy in cases with advanced disease suggested generally low response rates in patients with epidermoid carcinoma and a [28, 29] A recent approach to the management of inoperable cases of lung carcinoma has been to combine chemotherapy with "reductive" surgery; that is, to surgically remove tumors following regression with chemotherapy. Preliminary data are encouraging [29] . Reducing the bulk of the tumor is theoretically advantageous as a means of rendering additional cytotoxic therapy more effective.
In patients with non-small cell carcinoma with advanced disease, various drug combinations are reported to induce tumor regression considered superior to that achieved with single agents, although few controlled trials comparing single agents to drug combinations have been carried out. Laing [30] , in a randomized study, found that combination chemotherapy was associated with shorter median survival than single agent therapy or a control group (untreated), but better symptomatic control of the disease developed in survivors of combination chemotherapy.
Intensive therapy with drug combinations generally yields response rates higher than those reported in the past. However, responses are seldom complete. Survival times vary from three to ten months, and rarely exceed one year [31] [32] [33] [34] [35] [36] [37] . An exception is the trial of Egan et al. in which median survival of 17 months was achieved [28] . Table 2 summarizes data from some recent selected clinical trials in non-small cell carcinoma of the lung. It is apparent that high response rates in some series are not verified in subsequent trials involving larger numbers of patients [12, 34, 35, 38] . Additionally, there is often serious morbidity and occasional lethal complications associated with intensive therapy. Nevertheless, numerous other regimens are in the process of clinical trial or reporting in an attempt to find therapies of greater benefit and less toxicity.
Preliminary studies with newer agents, vindesine, m-AMSA, the acridine dye derivative 4'-9-acridinyldamino-methane-sulfone-M-anisidine, and maytansine suggest that they may exert anti-tumor effects in non-small cell carcinoma [42] [43] [44] [45] . Vindesine is being included in current trials of combined therapy for lung neoplasms [39] .
In randomized and in sequential trials, there does not appear to be a clear advantage for intensive treatment of non-small cell carcinoma of the lung, as compared to single agent therapy [13, 14, 30] . Careful staging and evaluation of factors that influence response rate appear to identify patient groups who benefit from treatments-those with limited extent of disease and good performance status.
Non-small cell tumors remain unresponsive to chemotherapy in the majority of cases. In the individual patients, the very considerable morbidity of treatment (although tolerable in most instances) must be a major factor influencing the choice for or against chemotherapy for this disease. [11, 27] . As in other neoplastic diseases, current trends are toward intensive treatment regimens, including use of multiple drugs, cyclic treatment of from six to 24 months' duration and combined modality usage, with both radiation therapy and chemotherapy.
Concomitant with increased interest in the therapeutic management of small cell carcinoma has been the development of sophistication in defining the extent of the disease and assessing the impact of clinical parameters upon the outcome. The predominant factor affecting survival appears to be the extent of disease at the time of diagnosis [1, 46] . Patients [48] ; patients with bone marrow involvement and particularly those with associated peripheral blood cytopenias have shortened survival [49] . Patients with a solitary extra pulmonary focus of metastasis may have a more favorable outcome than those with widespread metastases [50] .
Numerous drugs have demonstrated significant antitumor effects in small cell carcinoma of the lung (Table 1) [1, 11] . Following the demonstration of the effectiveness of alkylating agents, the use of cyclophosphamide following radiation treatment to the primary tumor was assessed to determine whether survival could be favorably influenced [51] . Subsequently, drug combinations came into widespread clinical use as a consequence of studies in small numbers of cases suggesting increased response rate and longer survival [52, 53] . Most of the clinical trials utilized survival data from published reports-few controlled studies with less intensive regimens and single agent treatment have been carried out. Nevertheless, the results achieved with intensive therapeutic regimens are impressive, as reviewed by Greco et al. [9] (Table 3) .
In a randomized study reported in 1975 [54] , Laing compared a four-drug combination to the use of radiotherapy in patients with both limited and extensive In two reports [55, 56] The elucidation of biologic events in the course of treatment, that is, differentiation, drug resistance, and host factors, will probably be the most significant factors leading to ultimate control of the disease.
